Loading clinical trials...
Loading clinical trials...
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AVM Biotechnology Inc
NCT05902169 · Glioblastoma, Recurrent Glioblastoma, and more
NCT06532279 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, and more
NCT07003542 · Glioblastoma, Brain Tumor
NCT05303467 · Glioblastoma Multiforme, Recurrent Glioblastoma
NCT07088211 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions